Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR)
Authors' conclusion
In conclusion, this population-based study conducted in patients with acromegaly revealed that faster remission time, surgical intervention and treatment with SMA are linked to improved survival outcomes.
Study context
- Population
- Individuals with acromegaly in the UK Acromegaly Register; median age at diagnosis 47.3 (36.5–57.8) years, 48% females, 61% white
- Participants
- 3,569 individuals
- Exposure
- Time to first remission and survival
- Outcome
- Effect of time to remission (GH controlled at ≤2 μg/L) on survival
Methodological detailsregistry-based, accelerated failure time model
- Registry-based
- Accelerated failure time model
Main finding
As reported in the abstract
Survival by time to first remission
- Time to first remission had a significant effect on survival
- p < .001
- Survival change per 1-year increase in time to first remission
- median 1% reduction
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| Survival by treatmentSurgery vs No surgery · higher with surgery · adjusted for covariates | survival rate higher 52% | P < 0.001 |
| Survival by treatmentSMA vs Dopamine agonists · higher with SMA · adjusted for covariates | survival rate higher 18% | P = 0.01 |
| Survival by treatmentConventional radiotherapy vs No radiotherapy · lower with radiotherapy · adjusted for covariates | survival rate lower 21% | P < 0.001 |
First remission
- Individuals with first remission
- 2472
- Median time to first remission
- 1.92 (0.70-6.58) years
Original publication
Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR). Clin Endocrinol (Oxf). Published 16 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →